Mesoblast (MESO) to Release Quarterly Earnings on Thursday

Mesoblast (NASDAQ:MESO) is anticipated to announce its earnings results on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $2.39 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Mesoblast Stock Down 0.9 %

NASDAQ:MESO opened at $16.23 on Tuesday. The stock has a 50-day simple moving average of $17.91 and a 200-day simple moving average of $11.91. Mesoblast has a 1 year low of $1.91 and a 1 year high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Analyst Ratings Changes

Several research analysts have recently issued reports on MESO shares. Piper Sandler reaffirmed an “overweight” rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.